Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANNETTE F OKAI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1275755399
CMS profile
12192
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$81,639.43

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 4; records 151–172 of 172 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANNETTE F OKAI

NPI 1275755399 · CMS profile ID 12192

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–172 of 172 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275755399?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANNETTE F OKAI, NPI 1275755399, CMS profile ID 12192. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–172 of 172 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275755399?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANNETTE F OKAI, NPI 1275755399, CMS profile ID 12192. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–172 of 172 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275755399?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANNETTE F OKAI, NPI 1275755399, CMS profile ID 12192, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–172 of 172 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275755399?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $81,639.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–172 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $1,152.0004/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825653 CMS
Celgene Corporation $2,170.0004/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783728979 CMS
Biogen, Inc. $77.6504/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825673 CMS
EMD Serono, Inc. $1,100.0004/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849148115 CMS
EMD Serono, Inc. $2,200.0004/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849179841 CMS
GENZYME CORPORATION $2,184.0003/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843598755 CMS
Biogen, Inc. $1,152.0003/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825651 CMS
Celgene Corporation $300.0003/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783728993 CMS
Biogen, Inc. $1,152.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825649 CMS
EMD Serono, Inc. $19.1203/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849148119 CMS
Alexion Pharmaceuticals, Inc. $23.3303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783112097 CMS
EMD Serono, Inc. $1,320.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849180187 CMS
Genentech, Inc. $1,500.0003/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835889265 CMS
Genentech USA, Inc. $2,595.0003/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835889259 CMS
GENZYME CORPORATION $4,250.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843598883 CMS
GENZYME CORPORATION $4,585.0003/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843598929 CMS
Lilly USA, LLC $19.9303/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818944564 CMS
EMD Serono, Inc. $1,531.2502/25/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849151767 CMS
E.R. Squibb & Sons, L.L.C. $1,420.0002/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783647199 CMS
EMD Serono, Inc. $275.0002/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849179333 CMS
Merck KGaA $330.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840490471 CMS
Biogen, Inc. $3.1701/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $236,283.25 370
PY2020 $87,516.78 136
PY2021 $81,639.43 172
PY2022 $125,789.60 259
PY2023 $106,476.32 266
PY2024 $55,628.54 188
PY2025 $36,337.51 156

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,514.62 2
PY2025 Principal investigator $812,192.70 47
PY2024 Recipient $11,283.71 12
PY2024 Principal investigator $787,741.98 65
PY2023 Recipient $3,051.53 4
PY2023 Principal investigator $647,139.58 98
PY2022 Recipient $1,650.00 1
PY2022 Principal investigator $460,296.68 22
PY2021 Recipient $7,477.28 3
PY2021 Principal investigator $507,876.93 20
PY2020 Recipient $356.00 1
PY2020 Principal investigator $80,156.10 35
PY2019 Recipient $2,871.82 6
PY2019 Principal investigator $122,692.80 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $9,648.00 12/19/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631303
Principal investigator 1 ModernaTX, Inc. $7,700.00 12/17/2025 Non-covered Recipient Entity
SATURN RESEARCH SOLUTIONS LLC
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962137
Principal investigator 1 ModernaTX, Inc. $2,235.00 12/17/2025 Non-covered Recipient Entity
SATURN RESEARCH SOLUTIONS LLC
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962139
Principal investigator 1 Genentech, Inc. $3,317.00 11/25/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631298
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 11/20/2025 Non-covered Recipient Entity
North Texas Institute of Neurology & Headache
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198399
Principal investigator 1 GENZYME CORPORATION $23,453.00 11/17/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081779
Principal investigator 1 GENZYME CORPORATION $13,575.00 11/17/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081784
Principal investigator 1 Novartis Pharmaceuticals Corporation $786.00 11/01/2025 Non-covered Recipient Entity
SATURN RESEARCH SOLUTION
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190314161
Principal investigator 1 Genentech, Inc. $6,634.00 10/15/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631295
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,301.52 10/07/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY AND HEADACHE
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190312205
Principal investigator 1 GENZYME CORPORATION $29,925.00 10/06/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081734
Recipient F. Hoffmann-La Roche AG $424.06 10/03/2025 Covered Recipient Physician Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial No dispute reported 06/30/2026 1211534617
Recipient F. Hoffmann-La Roche AG $1,090.56 10/02/2025 Covered Recipient Physician Efficacy Tolerability of Ocrelizumab in African Americans Hispanic Americans vs Caucasians No dispute reported 06/30/2026 1211534621
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117962
Principal investigator 1 Genentech, Inc. $36,902.00 09/17/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631289
Principal investigator 1 GENZYME CORPORATION $18,538.00 09/15/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226081726
Principal investigator 1 ModernaTX, Inc. $66.24 08/28/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY & HEADACHE (NTINH) - PLANO
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962129
Principal investigator 1 ModernaTX, Inc. $199.00 08/28/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY & HEADACHE (NTINH) - PLANO
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962131
Principal investigator 1 Genentech, Inc. $7,378.00 08/21/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631285
Principal investigator 1 ModernaTX, Inc. $12,486.30 08/06/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY & HEADACHE (NTINH) - PLANO
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962133
Principal investigator 1 ModernaTX, Inc. $957.28 08/06/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY & HEADACHE (NTINH) - PLANO
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962135
Principal investigator 1 ModernaTX, Inc. $624.31 08/06/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY & HEADACHE (NTINH) - PLANO
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252962141
Principal investigator 1 GENZYME CORPORATION $11,875.00 08/04/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081694
Principal investigator 1 GENZYME CORPORATION $51,175.00 08/04/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081698
Principal investigator 1 TG Therapeutics, Inc. $6,904.00 07/30/2025 Non-covered Recipient Entity
North Texas Institute of Neurology & Headache
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198381
Principal investigator 1 Genentech, Inc. $16,307.00 07/11/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211631252
Principal investigator 1 Genentech, Inc. $12,662.00 06/17/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631265
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 06/12/2025 Non-covered Recipient Entity
North Texas Institute of Neurology & Headache
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198359
Principal investigator 1 GENZYME CORPORATION $950.00 06/09/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081682
Principal investigator 1 Novartis Pharmaceuticals Corporation $145,396.72 05/27/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY AND HEADACHE
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307565
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117955
Principal investigator 1 Genentech, Inc. $1,980.00 05/22/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631261
Principal investigator 1 Genentech, Inc. $6,634.00 05/21/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631256
Principal investigator 1 GENZYME CORPORATION $8,875.00 05/19/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081686
Principal investigator 1 GENZYME CORPORATION $5,100.00 04/28/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081662
Principal investigator 1 Genentech, Inc. $10,311.00 04/25/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631280
Principal investigator 1 Genentech, Inc. $37,365.00 04/17/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211631248
Principal investigator 1 Genentech, Inc. $18,451.00 04/02/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631276
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 03/25/2025 Non-covered Recipient Entity
North Texas Institute of Neurology & Headache
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198353
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117958
Principal investigator 1 Alexion Pharmaceuticals, Inc. $5,710.90 03/21/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY AND HEADACHE
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185545203
Principal investigator 1 GENZYME CORPORATION $16,425.00 03/17/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081634
Principal investigator 1 Genentech, Inc. $30,280.00 02/14/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631269
Principal investigator 1 TG Therapeutics, Inc. $6,904.00 01/31/2025 Non-covered Recipient Entity
North Texas Institute of Neurology & Headache
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198333
Principal investigator 1 Genentech, Inc. $15,640.00 01/22/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY + HEADACHE
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211631272
Principal investigator 1 GENZYME CORPORATION $8,550.00 01/13/2025 Non-covered Recipient Entity
North Texas Institute Of Neurology Headache
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226081645
Principal investigator 1 Novartis Pharmaceuticals Corporation $197,524.79 01/09/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY AND HEADACHE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307561
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 01/02/2025 Non-covered Recipient Entity
North Texas Institute of Neurology & Headache
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198351
Principal investigator 1 Novartis Pharmaceuticals Corporation $72.00 01/01/2025 Non-covered Recipient Entity
NORTH TEXAS INSTITUTE OF NEUROLOGY AND HEADACHE
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190307563